Archives

GLP-1 Drugs May Benefit Cancer Patients With Brain Lesions

(MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients…

Q&A: How small steps can help GLP-1 users build healthier habits

A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It’s a simple premise: What if something as small as a digital nudge could put someone on the path to healthier habits while taking GLP-1 medications?

FDA Warns Novo Nordisk of Unreported GLP-1 Side Effects

The FDA has issued a warning letter to Novo Nordisk saying the maker of Ozempic and Wegovy failed to report potential side effects in patients who took the medications. The agency cited three deaths among patients, including one who died by suicide. The FDA says the company did not report the deaths within the agency’s required time and that it also failed to investigate or report the suicide.

GLP-1 medication changes may support long-term weight management

Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn’t switch, according to a new study by UT Southwestern Medical Center researchers. The findings, published in JAMA Network Open, suggest that medication changes are not uncommon among patients undergoing weight loss and that clinicians should encourage them to change GLP-1RAs if necessary to promote continuity of care.